Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Biohaven Ltd. publishes a filing, an earnings call transcript or a press release.

Get BHVN alerts

About Bruce Car

Agios Pharmaceuticals, Inc. reported in an 8-K filed May 18, 2022 that Bruce Car resigned as chief scientific officer, effective July 31, 2022. The proxy statement of Biohaven Ltd. reports total compensation of $3,935,078 for Bruce Car in fiscal 2024, including a base salary of $515,567. Disclosed compensation is on record for 7 fiscal years. Biohaven Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biohaven Ltd. includes Vlad Coric (CEO and Board Member), Matthew Buten (CFO), Warren Volles (General Counsel) and 7 others.

“On May 15, 2022, Bruce Car, Ph.D. notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign as chief scientific officer of the Company, effective July 31, 2022.”
Agios Pharmaceuticals, Inc. Form 8-K, filed May 18, 2022 · Read the filing

Affiliation history

Company network

Leadership on record at Biohaven Ltd.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Biohaven Ltd. (BHVN) $515,567 $3,935,078
2023 Biohaven Ltd. (BHVN) $489,850 $2,584,248
2022 Agios Pharmaceuticals, Inc. (AGIO) $309,429 $1,852,384
2022 Biohaven Ltd. (BHVN) $121,250 $1,773,908
2021 Agios Pharmaceuticals, Inc. (AGIO) $515,000 $2,803,973
2020 Agios Pharmaceuticals, Inc. (AGIO) $494,318 $3,228,043
2019 Agios Pharmaceuticals, Inc. (AGIO) — —
2018 Agios Pharmaceuticals, Inc. (AGIO) — —

Recent activity